World News: 12:45 GMT Thursday 6th December 2018. [Research and Markets via Globe Newswire via SPi World News]
Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering.
The rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULE
PART 09: MARKET SEGMENTATION BY TYPE OF RA
PART 10: CUSTOMER LANDSCAPEPART 11: REGIONAL LANDSCAPE
PART 12: DECISION FRAMEWORKPART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
PART 16: VENDOR ANALYSIS
For more information about this report visit
Research and Markets also offers services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs
Globe Newswire: 12:45 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.